GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnos Inc (OTCPK:DGNOF) » Definitions » EBITDA Margin %

Diagnos (Diagnos) EBITDA Margin % : -1,215.38% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Diagnos EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Diagnos's EBITDA for the three months ended in Dec. 2023 was $-0.47 Mil. Diagnos's Revenue for the three months ended in Dec. 2023 was $0.04 Mil. Therefore, Diagnos's EBITDA margin for the quarter that ended in Dec. 2023 was -1,215.38%.


Diagnos EBITDA Margin % Historical Data

The historical data trend for Diagnos's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnos EBITDA Margin % Chart

Diagnos Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -822.95 -884.03 -716.04 -557.35 -432.39

Diagnos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -338.89 -878.00 -1,421.88 -1,787.50 -1,215.38

Competitive Comparison of Diagnos's EBITDA Margin %

For the Health Information Services subindustry, Diagnos's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnos's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Diagnos's EBITDA Margin % falls into.



Diagnos EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Diagnos's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-1.535/0.355
=-432.39 %

Diagnos's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.474/0.039
=-1,215.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diagnos  (OTCPK:DGNOF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Diagnos EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Diagnos's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnos (Diagnos) Business Description

Traded in Other Exchanges
Address
7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, UAE, Saudi Arabia, Mexico, Costa Rica, and others. The company's key revenue is derived from Canada.

Diagnos (Diagnos) Headlines

From GuruFocus

DIAGNOS Announces Symbol Change on the OTCQB: DGNOD

By GlobeNewswire GlobeNewswire 05-08-2019

DIAGNOS Announces Closing of Private Placement

By GlobeNewswire GlobeNewswire 11-25-2022

DIAGNOS Announces Final Closing of Private Placement

By GlobeNewswire GlobeNewswire 11-21-2018